Phase i trials: From traditional to newer approaches part II

Journal of Psychiatric Practice

Volumn 17, Issue 4, 2011, Pages 277-284

  MacAluso, Matthew ^a   Krams, Michael ^b   Preskorn, Sheldon H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

adaptive trial designs; biomarkers; drug development; novel molecular entities; phase I clinical trials

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CENTRAL NERVOUS SYSTEM AGENTS; DOPAMINE 2 RECEPTOR; NEUROLEPTIC AGENT;

ARTICLE; CANCER PATIENT; DECISION MAKING; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; MAXIMUM TOLERATED DOSE; MENTAL PATIENT; NORMAL HUMAN; OPTIMAL DRUG DOSE; PHASE 1 CLINICAL TRIAL (TOPIC); STUDY DESIGN;

BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDPOINT DETERMINATION; HUMANS; PHARMACEUTICAL PREPARATIONS; RESEARCH DESIGN;

EID: 80051778408     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000400265.37666.4e     Document Type: Article

References (28)

1. Macaluso M, Krams M. Preskorn SH. Phase I trials: From traditional to newer approaches. Part I. J Psychiatr Pract 2011;17:200-3.
2. Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: The pharmaceutical industrys grand challenge. Nat Rev Drug Discov 2010;9:203-14.
3. Kraemer HC, Morgan GA, Leech NL, et al. Measures of clinical significance. J Am Acad Child Adolesc Psych 2003;42:1524-9. (Pubitemid 39585985)
4. Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997;61:275-91. (Pubitemid 27145429)
5. Spilker B. Guide to clinical trials. Lippincott Williams & Wilkins; 1991.
6. Gilles C, Luthringer R. Pharmacological models in healthy volunteers: Their use in the clinical development of psychotropic drugs. J Psychopharmacol 2007;21:272-82. (Pubitemid 46934050)
7. Agrawal M, Emanuel EJ. Ethics of phase 1 oncology studies: Reexamining the arguments and data. JAMA 2003;290:1075-82. (Pubitemid 37430449)
8. Emanuel EJ. A phase I trial on the ethics of phase I trials. J Clin Oncol 1995;13:1049-51.
9. Preskorn SH. If lack of concentration didnt cause the fall, what did? Journal of Practical Psychiatry and Behavioral Health 1996;2:364-7.
10. de Visser SJ, van der Post J, Pieters MS, et al. Biomarkers for the effects of antipsychotic drugs in healthy volunteers. Br J Clin Pharmacol 2001;512:119-32. (Pubitemid 32219735)
11. Conn PJ, Roth BL. Opportunities and challenges of psychiatric drug discovery: Roles for scientists in academic, industry, and government settings. Neuropsycho pharmacology 2008;33:2048-60. (Pubitemid 351992094)
12. Gallo P, Chuang-Stein C, Dragalin V, et al. Executive summary of the PhRMA Working Group on adaptive designs in clinical drug development. J Biopharm Stat 2006;16:275-83.
13. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149-61.
14. Krams M, Burman CF, Dragalin V, et al. Adaptive designs in clinical drug development: Opportunities, challenges, and scope reflections following PhRMAs November 2006 workshop. J Biopharm Stat 2007;17:957-64. (Pubitemid 350135823)
15. Krams M, Sharma S, Dragalin V, et al. Adaptive approaches in clinical drug development: Opportunities and challenges in design and implementation. Pharmaceut Med 2009;23:139-48.
16. Shen J, Preskorn S, Dragalin V, et al. How adaptive trial designs can increase efficiency in psychiatric drug development: A case study. Innov Clin Neurosci 2011, in press.
17. Chow SC, Chang M. Adaptive design methods in clinical trials- A review. Orphanet J Rare Dis 2008;3:11.
18. OQuigley J, Pepe M, Fisher L. Continual reassessment method: A practical design for phase 1 clinical trials in cancer. Biometrics 1990;46:33-48. (Pubitemid 20245604)
19. Gaydos B, Krams M, Perevozskaya I, et al. Adaptive doseresponse studies. Drug Info J 2006;40:451-61.
20. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). E15 definitions for genomic biomarkers, pharmacogenetics, genomic data, and sample coding categories, April 2008 (available at www.fda.gov/downloads /RegulatoryInformation/Guidances/ ucm129296.pdf, accessed July 7, 2011.
21. Chapel S, Hutmacher MM, Haig G, et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009;49:1297-1308.
22. Preskorn S, DEmpaire I, Baker B, et al. EVP-6124, an alpha-7 nicotinic agonist produces normalizing effects on evoked response biomarkers and cognition in patients with chronic schizophrenia on stable antipsychotic therapy. Poster presented at the 2009 American College of Neuropsychopharmacology meeting, Hollywood, FL, December, 2009.
23. U.S. Department of Health and Human Services, FDA, CDER, CBER. E16 genomic biomarkers related to drug response: Context, structure, and format of qualification submissions (draft guidance) (available at www.fda.gov /downloads/Drugs/GuidanceComplianceRegulatoryInforma tion/Guidances/UCM174433. pdf, accessed July 7, 2011).
24. U.S. Department of Health and Human Services, FDA, CDER, CBER. Guidance for industry: Pharmacogenomic data submissions (available at www.fda.gov/downloads /Drugs/GuidanceComplianceRegulatoryInformation/Guida nces/ucm079849.pdf, accessedJuly 7, 2011).
25. Wong DF, Tauscher J, Grnder G. The role of imaging in proof of concept for CNS drug discovery and development. Neuropsychopharmacology 2009;34:187-203.
26. Sweeney JA, Bauer KS, Keshavan MS, et al. Adverse effects of risperidone on eye movement activity: A comparison of risperidone and haloperidol in antipsychotic-naive schizophrenic patients. Neuropsychopharmacology 1997;16:217-28. (Pubitemid 27144373)
27. Leuchter AF, Cook IA, Marangell LB, et al. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: Results of the BRITE-MD study. Psychiatry Res 2009;169:124-31.
28. Steiger A, Kimura M. Wake and sleep EEG provide biomarkers in depression. J Psychiatr Res 2010;44:242-52.